| Literature DB >> 21437240 |
Matthew J Billard1, Amanda L Gruver, Gregory D Sempowski.
Abstract
BACKGROUND: Productive thymopoiesis is essential for a robust and healthy immune system. Thymus unfortunately is acutely sensitive to stress resulting in involution and decreased T cell production. Thymic involution is a complication of many clinical settings, including infection, malnutrition, starvation, and irradiation or immunosuppressive therapies. Systemic rises in glucocorticoids and inflammatory cytokines are known to contribute to thymic atrophy. Little is known, however, about intrathymic mechanisms that may actively contribute to thymus atrophy or initiate thymic recovery following stress events. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2011 PMID: 21437240 PMCID: PMC3060875 DOI: 10.1371/journal.pone.0017940
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Endotoxin-induced acute thymic atrophy.
Female mice were administered either saline or E. coli LPS. (A) Thymus weight, (B) Total number of thymocytes, (C) mTREC/mg thymus, (D) Absolute number of DP thymocytes. Representative flow cytometry plots of thymocyte phenotype were determined at (E) one and (F) three days post treatment. (G) Representative hematoxylin and eosin staining of thymus tissue four days post LPS challenge. *p<0.05 compared to saline-treated controls (n = 5).
Endotoxin-induced peak cytokine levels in mice (n = 5).
| Treatment | ||||
| Cytokine | Peak Hr | Saline | LPS | p-value |
| TNF-α | 1 | 372±371 | 59,200±15,9 | 0.0000349 |
| IL-3 | 2 | 3.10±4.28 | 18.6±12.9 | 0.0338 |
| IL-4 | 2 | 1.01±0.372 | 1.75±0.667 | 0.0636 |
| IL-10 | 2 | 20.1±22.4 | 572±376 | 0.0113 |
| IL-13 | 2 | 2.04±4.56 | 72.1±21.8 | 0.000110 |
| MCP-1 | 2 | 0.780±1.74 | 39,900±19,800 | 0.00309 |
| MIP-1β | 2 | 7.89±4.88 | 36,800±8,000 | 0.0000134 |
| IL-2 | 4 | 0.022±0.05 | 16.4±8.50 | 0.00259 |
| IL-12p40 | 4 | 193±62.9 | 24,000±5,770 | 0.0000155 |
| IL-12p70 | 4 | 23.1±15.4 | 726±217 | 0.0000889 |
| KC | 4 | 7.83±2.09 | 58,100±34,800 | 0.00574 |
| GM-CSF | 4 | 0.526±1.18 | 99.8±15.3 | 0.000000515 |
| MIP-1α | 4 | 12.0±26.8 | 23,400±2,320 | 0.0000000162 |
| Rantes | 4 | 121±47.2 | 8,070±2,820 | 0.000234 |
| IL-1α | 6 | 73.0±6.89 | 274±97.5 | 0.00174 |
| IL-1β | 6 | 73.6±60.1 | 386±81.5 | 0.000126 |
| IL-5 | 6 | 18.1±23.1 | 843±573 | 0.0123 |
| IL-6 | 6 | 77.1±164 | 14,900±6,080 | 0.000622 |
| IL-9 | 6 | 34.7±12.8 | 72.7±37.4 | 0.0643 |
| IL-17 | 6 | 36.7±79.6 | 493±247 | 0.00439 |
| Eotaxin | 6 | 131±257 | 9,910±3,860 | 0.000478 |
| G-CSF | 6 | 18.9±18.4 | 16,100±19,900 | 0.155 |
| IFN-γ | 6 | 3.45±3.29 | 80.2±46.8 | 0.00638 |
Peak Hr: time of cytokine peak level post-treatment (in hours).
Endotoxin-induced intrathymic cytokine gene expression.
| Probeset ID | Cytokine | Fold Change | Adjusted p-value |
| 1419607_at | TNF-α | 2.6 | 0.0071 |
| 1450566_at | IL-3 | 1.1 | 0.4082 |
| 1449864_at | IL-4 | −1.1 | 0.7036 |
| 1450330_at | IL-10 | 5.4 | 0.0025 |
| 1420802_at | IL-13 | 1.2 | 0.2939 |
| 1420380_at | MCP-1 (CCL2) | 9.8 | 0.0024 |
| 1421578_at | MIP-1β (CCL4) | 5.9 | 0.0020 |
| 1449990_at | IL-2 | 1.2 | 0.2301 |
| 1419530_at | IL-12p40 | 2.0 | 0.0282 |
| 1449497_at | IL-12p40 | 1.6 | 0.0980 |
| 1425454_a_at | IL-12p35 | 1.0 | 0.8441 |
| 1419209_at | KC (CXCL1) | 71.7 | 0.0012 |
| 1457644_s_at | KC (CXCL1) | 26.0 | 0.0017 |
| 1441855_x_at | KC (CXCL1) | 3.8 | 0.0099 |
| 1427429_at | GM-CSF (Csf2) | 1.8 | 0.0160 |
| 1419561_at | MIP-1α (CCL3) | 57.0 | 0.0012 |
| 1418126_at | Rantes (CCL5) | 11.8 | 0.0046 |
| 1421473_at | IL-1α | 4.4 | 0.0096 |
| 1449399_a_at | IL-1β | 3.5 | 0.0030 |
| 1450550_at | IL-5 | 1.3 | 0.1738 |
| 1450297_at | IL-6 | 37.5 | 0.0018 |
| 1450565_at | IL-9 | 1.1 | 0.3694 |
| 1421672_at | IL-17 | 1.7 | 0.0164 |
| 1417789_at | Eotaxin (CCL11) | 1.6 | 0.0334 |
| 1419427_at | G-CSF (Csf3) | 24.7 | 0.0028 |
| 1425947_at | IFN-γ | 1.1 | 0.5898 |
p-values adjusted using Benjamini-Hochberg false discovery rate correction.
Significant differentially expressed genes overrepresented in the gene ontology.
| Gene ontology category | p-value | #/GO size | Top 25 fold changes per GO category | % genes change | Mean FC |
| GO:0001775 | 2.51×10−11 | 123/201 |
| 41.5% up | 2.25 |
| Cell activation |
| 58.5% down | −2.70 | ||
|
| |||||
| GO:0051301 | 7.79×10−10 | 131/225 |
| 11.5% up | 2.17 |
| Cell division |
| 88.5% down | −2.82 | ||
|
| |||||
| GO:0046649 | 1.51×10−9 | 101/165 |
| 35.6% up | 2.22 |
| Lymphocyte activation |
| 64.3% down | −2.74 | ||
|
| |||||
| GO:0000278 | 6.19×10−9 | 138/245 |
| 16.7% up | 2.33 |
| Mitotic cell cycle |
| 83.3% down | −2.68 | ||
|
| |||||
| GO:0065007 | 7.48×10−9 | 2109/5114 | Adamts1, Aldh1a1, | 49.7% up | 2.63 |
| Biological regulation | F3, Ifi204, Igfbp3, Iigp1, Il6, Lox, Mt1, Mt2, Orm1, Osmr, | 50.3% down | −2.30 | ||
| Pdk4, Pth, Ptx3, Ramp3, Rorc, | |||||
| GO:0006955 | 1.23×10−8 | 119/208 |
| 74.8% up | 6.85 |
| Immune response |
| 25.2% down | −2.77 | ||
| Cxcl5, Cxcl9, Gbp2, Gbp3, Lilrb4, Ptx3, Rsad2, Serpina3g | |||||
| GO:0006950 | 5.06×10−8 | 453/979 | Ccl12, Ccl2, Ccl3, Ccl5, Cd14, Cfb, Cxcl1, Cxcl10, Cxcl13, | 55.8% up | 4.81 |
| Response to stress | Cxcl2, Cxcl5, Cxcl9, Defb1, | 44.2% down | −2.41 | ||
| Rsad2, Saa1, Saa3, Serpina3n, | |||||
| GO:0002521 | 4.07×10−7 | 72/118 |
| 25.0% up | 4.22 |
| Leukocyte differentiation |
| 75.0% down | −2.88 | ||
|
| |||||
| GO:0048534 | 4.81×10−7 | 155/296 |
| 41.9% up | 3.89 |
| Hematop./lymph. organ devel. | Epas1, Gadd45g, | 58.1% down | −2.18 | ||
|
| |||||
| GO:0002376 | 5.19×10−7 | 137/261 |
| 46.7% up | 2.69 |
| Immune system process | Ifi30, Orm1, | 53.3% down | −2.50 | ||
| Selp, |
Overrepresented GO p-value determined by hypergeometric test.
Number (#) of individual significant genes present in GO category out of number possible in defined category (GO size).
Based on absolute value of fold change. Down regulated genes in italics.
Percentage of individual significant genes that grouped to GO category, showing both up- and down- regulated genes.
Mean fold changes of genes in each GO category, up- and down- regulated genes averaged separately.
Top statistically significant pathwaysa.
| Pathway name | p-value |
| Cytoskeleton remodeling: Cytoskeleton remodeling | 3.75×10−15 |
| Cytoskeleton remodeling: TGF, WNT and cytoskeletal remodeling | 7.19×10−15 |
| Immune response: IL-17 signaling pathways | 1.45×10−13 |
| Cell cycle: Chromosome condensation in prometaphase | 1.15×10−12 |
| Immune response: CD28 signaling | 1.07×10−10 |
| Immune response: Immunological synapse formation | 1.11×10−10 |
| Cell adhesion: Chemokines and adhesion | 1.67×10−10 |
| Cell cycle: Regulation of G1/S transition (part 2) | 3.09×10−10 |
| Immune response: T cell receptor signaling pathway | 4.36×10−10 |
| Cell cycle: Cell cycle (generic schema) | 9.56×10−10 |
Significance based on number of genes within defined pathways.
Top differentially-affected pathwaysa.
| Pathway name | p-value |
| Immune response: TLR3 and TLR4 induce TICAM1 | 3.40×10−03 |
| Neurophysiological process: ACM regulation of nerve impulse | 2.59×10−03 |
| Development: EGFR signaling pathway | 1.47×10−09 |
| Immune response: CD28 signaling | 1.07×10−10 |
| Immune response: Regulation of T cell function by CTLA-4 | 1.18×10−08 |
| Immune response: CD40 signaling | 5.09×10−08 |
| Inhibitory action of Lipoxins and Resolvin E1 on neutrophil functions | 8.41×10−02 |
| Immune response: MIF-JAB1 signaling | 8.24×10−03 |
| Ca(2+)-dependent NF-AT signaling in Cardiac Hypertrophy | 2.02×10−02 |
| Muscle contraction: EDG5-mediated smooth muscle contraction | 2.03×10−02 |
Significance reflects absolute differences (by standard deviation) with respect to saline vs. LPS.
Figure 2Cytoskeleton and matrix remodeling during acute thymic atrophy.
The cytoskeleton remodeling pathway scored highest in Metacore pathway analysis based on number of significant genes (p-value = 3.75×10−15). Red genes represent significant increases in mRNA levels and blue genes represent significant decreases in mRNA levels in thymus tissue following LPS treatment. Mean fold changes are given. Green arrows indicate positive influence and red T-bars indicate negative influence. Arrows may represent multiple steps. Plasma membrane is shown in gray. A detailed version of the original Metacore pathway is found as Figure S2. A full legend of all GeneGo pathway map symbols is in Figure S9 or at http://www.genego.com/pdf/MC_legend.pdf.
Figure 3Modulation of IL-17 signaling during acute thymic atrophy.
The IL-17 pathway ranked as the third most statistically significant pathway (p-value = 1.45×10−13) using Metacore pathway analysis. This pathway includes genes for both secreted pro-inflammatory cytokines and the intracellular response through IL-17R. Red genes represent significant increases in mRNA levels and blue genes represent significant decreases in mRNA levels in thymus tissue following LPS treatment. Mean fold changes are given. Green arrows indicate positive influence. Arrows may represent multiple steps. Plasma membrane is shown in gray. Nuclear membrane is shown as dotted line. A detailed version of the original Metacore pathway is in Figure S4. A full legend of all GeneGo pathway map symbols is in Figure S9 or at http://www.genego.com/pdf/MC_legend.pdf.
Figure 4Dysregulation of immunological synapse formation during acute thymic atrophy.
The immune synapse pathway ranked sixth in statistical significance (p-value = 1.11×10−10) using Metacore analysis. Positive regulators of immune synapse formation and function were decreased following endotoxin stress in thymus. Red genes represent significant increases in mRNA levels and blue genes represent significant decreases in mRNA levels in thymus tissue following LPS treatment. Mean fold changes are given. Green arrows indicate positive influence. Arrows may represent multiple steps. Plasma membranes are shown in gray. A detailed version of the original Metacore pathway is in Figure S6. A full legend of all GeneGo pathway map symbols is in Figure S9 or at http://www.genego.com/pdf/MC_legend.pdf.
Figure 5Decreased CD28 signaling and activated CTLA-4 pathways during acute thymic atrophy.
The CD28 pathway ranked fifth in significance and fourth by differential expression (p-value = 1.07×10−10) using Metacore pathway analysis. Pathway analysis also determined the CTLA-4 pathway to be differentially affected (p-value = 1.18×10−8). CTLA-4, CD86 and CD80 mRNA levels were significantly increased while CD28 and TCR signaling-related mRNA levels were decreased. Red genes represent significant increases in mRNA levels and blue genes represent significant decreases in mRNA levels in thymus tissue following LPS treatment. Mean fold changes are given. Green arrows indicate positive influence and red T-bars indicate negative influence. Arrows may represent multiple steps. Plasma membranes are shown in gray. Nuclear membrane is shown as dotted line. A detailed version of the original Metacore pathways are in Figures S7 and S8. A full legend of all GeneGo pathway map symbols is in Figure S9 or at http://www.genego.com/pdf/MC_legend.pdf.